our Premium Content: News alerts, weekly reports and conference planners

GENE:

NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)

News alerts, weekly reports and conference planners

Three novel concomitant NTRK2 fusions in medullary thyroid carcinoma with diagnostic implications. (PubMed, Discov Oncol)

Tumors harboring these fusions respond dramatically to TRK inhibitors (e.g., larotrectinib, entrectinib, and repotrectinib), which selectively target the constitutively active fusion protein. Conclusively, this first report of three novel NTRK2 fusion transcript variants co-occurrence in an MTC patient expands the known spectrum of translocation partners in NTRK2 rearrangements. Prospective validation of their impact on TRK-targeted therapy efficacy and disease prognosis requires long-term follow-up.

6 days ago

Journal

NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)

Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib)

Retrospective Comparison of Operational Metrics Across Diagnostic Approaches for Molecular Testing in Lung and Colon Cancers in a Community-Based Setting. (PubMed, Arch Pathol Lab Med)

OFA balances TAT, QNS, and detection, whereas SO-NGS offers comprehensive detection with longer TAT and higher QNS. An optimized assay combining SGP's speed, OFA's reliability, and SO-NGS's comprehensiveness could improve outcomes.

7 days ago

Retrospective data • Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)

KRAS G12C • HER-2 amplification • HER-2 mutation • MET exon 14 mutation • KRAS G12 • KRAS amplification • NRAS G12

Oncomine Focus Assay

Do targeted NGS panels include NSCLC guideline-recommended biomarkers? (PubMed, Am J Manag Care)

Of 77 unique panels evaluated, only 5 captured all recommended biomarkers for mNSCLC. Ensuring targeted panels assess all relevant biomarkers is crucial for optimal patient treatment.

8 days ago

Journal • Next-generation sequencing

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)

MET amplification • MET exon 14 mutation • NTRK fusion

Adjuvant Larotrectinib in a Resected Secretory Carcinoma-Like Lung Adenocarcinoma Harboring EML4-NTRK3 Fusion: Case Report. (PubMed, JTO Clin Res Rep)

After adjuvant chemotherapy, maintenance larotrectinib was initiated based on proven TRK inhibitor efficacy in metastatic NTRK-fusion tumors and emerging evidence for targeted therapy benefit in driver-positive early stage lung adenocarcinoma. Our findings demonstrate the value of molecular pathology in the diagnostic journey of pulmonary malignancies, guiding rare fusion detection and supporting therapeutic decisions based on rare fusions in early stage disease.

8 days ago

Journal

NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • NTRK (Neurotrophic receptor tyrosine kinase)

NTRK fusion

Vitrakvi (larotrectinib)

Identification of NTRK3 fusions in plaque-like CD34-positive dermal fibroma. (PubMed, Histopathology)

NTRK3 gene fusions occur in a subset of plaque-like CD34-positive dermal fibromas, providing additional molecular insight into this rare superficial spindle cell lesion. Together with emerging literature, these findings support a role for recurrent kinase gene rearrangements in a subset of CD34-positive plaque-like superficial spindle cell tumours, while underscoring the continued importance of clinicopathologic correlation in defining this evolving spectrum.

8 days ago

Journal

NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • CD34 (CD34 molecule) • PPFIBP1 (PPFIA Binding Protein 1)

Corticosteroids for Managing TRK Inhibitor Withdrawal Pain: A Report on Two Cases. (PubMed, Curr Oncol)

Inhibitors such as larotrectinib, entrectinib and repotrectinib are used when cancer cells harbor NTRK1, NTRK2 or NTRK3 fusion...Short courses of prednisone for the former and dexamethasone for the latter were initiated after failure of standard analgesia... For patients experiencing TRK inhibitor withdrawal pain, especially when tapering down the inhibitor is not an available strategy, a short course of corticosteroids can provide lasting relief. These cases emphasize the importance of better understanding the mechanism underlying the relationship between NRTK, NGF and nociception.

9 days ago

Journal

NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)

NTRK positive • NTRK fusion

Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib) • prednisone • dexamethasone

14d

Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E. (PubMed, JCO Precis Oncol)

NCI-MATCH subprotocol Z1E demonstrates that larotrectinib offers clinically significant benefit with marked ORR across NTRK fusion-positive tumors with no clinically significant toxicities. These findings support the rationale for the US Food and Drug Administration's tissue-agnostic approval of larotrectinib for NTRK fusion-positive tumors. Our findings demonstrate the necessity of including NTRK1, NTRK2, and NTRK3 within comprehensive molecular assays of cancer to navigate patients to an easily administered and highly effective therapy.

14 days ago

Journal

NTRK positive • NTRK fusion

Vitrakvi (larotrectinib)

17d

BT8009-202: Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer (2025-521115-40-00)

P1/2, N=28, Recruiting, Bicycletx Limited

17 days ago

New P1/2 trial

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)

zelenectide pevedotin (BT8009)

21d

Pediatric NTRK-rearranged gliomas: A clinicopathological and molecular analysis of six cases. (PubMed, Pathol Res Pract)

This study expands the clinicopathological and molecular spectrum of pediatric NTRK-rearranged gliomas, including rare entities and complex fusion patterns, and supports routine NTRK testing in pediatric gliomas irrespective of histological grade.

21 days ago

Journal

TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ETV6 (ETS Variant Transcription Factor 6) • MSH2 (MutS Homolog 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CHEK1 (Checkpoint kinase 1) • NTRK (Neurotrophic receptor tyrosine kinase) • ARHGEF11 (Rho Guanine Nucleotide Exchange Factor 11)

NTRK fusion

23d

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC (clinicaltrials.gov)

P2, N=46, Not yet recruiting, Massachusetts General Hospital

23 days ago

New P2 trial • IO biomarker

ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RET fusion • ALK fusion • ROS1 fusion

carboplatin • pemetrexed • Yidafan (ivonescimab)

29d

The complexity of finding fit-for-purpose real-world data for oncology patients with rare NTRK gene fusions and a novel solution. (PubMed, ESMO Real World Data Digit Oncol)

The rarity of patients with NTRK gene fusion-positive cancer and number of eligible CGDBs/clinical sites present challenges for the identification of sufficient RWD sources that can be used in comparative effectiveness studies to contextualize results from single-arm trials. This approach provides a potential solution to identify fit-for-purpose RWD to support precision medicine for patients with cancer harboring rare genomic alterations.

29 days ago

Journal • Real-world evidence

NTRK fusion

Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK). (PubMed, Eur J Cancer)

Larotrectinib evoked broad and durable antitumor activity in a plethora of solid tumors with NTRK fusions. Safety profile was consistent with that of clinical trials, even after long-term administration. While NGS use is increasing, broader access is needed.

1 month ago

Journal

NTRK fusion

Vitrakvi (larotrectinib)